Company: BIAF
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024163
Chunk: 93

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part II, Item 3
Chunk 93
---
 Price Requirement by August 6, 2025, we may be eligible for additional time
to comply. In order to be eligible for such additional time, we will be required to meet the continued listing requirements for market
value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum
Bid Price Requirement, and must notify Nasdaq in writing of our intention to cure the deficiency during the second compliance period.
We intend to actively monitor the bid price of our Common Stock and will consider available options to regain compliance with the Nasdaq
listing requirements.

If
we fail to satisfy the continued listing requirements of The Nasdaq Capital Market, such as the corporate governance requirements, the
stockholder’s equity requirement, or the minimum closing bid price requirement, The Nasdaq Capital Market may take steps to de-list
our Common Stock or Tradeable Warrants. As reported in this Quarterly Report on Form 10-Q, our stockholders’ equity of approximately
$(2.1) million is below the Nasdaq required stockholders’ equity of $2.5 million. As a result, we will be unable to request an
additional 180-day period within which to comply with the Minimum Bid Price Requirement. Such a de-listing or even notification of failure
to comply with such requirements would likely have a negative effect on the price of our Common Stock and Tradeable Warrants and would
impair the ability to sell or purchase our Common Stock when you wish to do so. In the event of a de-listing, we would take actions to
restore our compliance with The Nasdaq Capital Market’s listing requirements, but we can provide no assurance that any such action
taken by us would allow our Common Stock to become listed again, stabilize the market price, improve the liquidity of our Common Stock,
prevent our Common Stock from dropping below The Nasdaq Capital Market minimum bid price requirement, or prevent future non-compliance
with The Nasdaq Capital Market’s listing requirements.

The
National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the
sale of certain securities, which are referred to as “covered securities.” Because our Common Stock is listed on The Nasdaq
Capital Market, it is a covered security. Although the states are preempted from regulating the sale of covered securities, the federal
statute does allow the states to investigate companies if there is a suspicion of fraud, and, if there is a finding